Skip to main content

Table 4 Factors associated with treatment success by 24 months among patients who were diagnosed with RR-TB between July 2011–June 2012 or between July 2013–July 2014 and who initiated DR-TB treatment in COJ (n = 537)

From: Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa

  n/N % RR 95% CI Adjusted RR 95% CI
Gender
 Female 75/258 29.1 Ref Ref Ref Ref
 Male 86/279 30.8 1.09 (0.79–1.49) 1.01 (0.74–1.41)
Age, years
  < 30 31/138 22.5 Ref Ref Ref Ref
 30–45 93/282 32.9 1.56 (1.02–2.37) 1.46 (0.94–2.25)
  ≥ 45 37/117 31.6 1.46 (0.89–2.38) 1.43 (0.86–2.37)
DR-TB classification
 RR-TB by Xpert MTB/RIF 96/237 40.5 4.36 (2.60–7.30) 4.31 (2.55–7.29)
 RIF mono-resistant TB 47/109 43.1 4.76 (2.70–8.36) 4.46 (2.07–7.95)
 MDR-TB 18/191 9.4 Ref Ref Ref Ref
HIV status at initiation
 HIV negative 14/61 22.1 0.58 (0.32–1.05) 0.75 (0.47–1.20)
 HIV positive on ART 120/351 33.4 Ref Ref Ref Ref
 HIV positive not on ART 16/77 19.5 0.6 (0.36–1.02) 0.73 (0.43–1.25)
 HIV status unknown 11/48 22.9 0.64 (0.33–1.21) 0.76 (0.43–1.24)
Registration year
 2011 19/55 34.5 Ref Ref Ref Ref
 2012 33/108 30.6 0.88 (0.50–1.56) 0.88 (0.49–1.56)
 2013 49/166 29.5 0.81 (0.47–1.37) 0.74 (0.43–1.28)
 2014 60/211 28.4 0.84 (0.50–1.41) 0.83 (0.49–1.41)
Time to treatment initiation
 Without delay 70/186 37.6 Ref Ref Ref Ref
 Delayed (deferred) 85/332 25.6 0.97 (0.71–1.33) 0.94 (0.66–1.33)
  1. RR Relative Risk, CI Confidence interval, RR-TB Rifampicin resistant TB, MTB Mycobacterium tuberculosis, MDR-TB Multi-drug resistant tuberculosis, XDR-TB Extensively drug-resistant tuberculosis; DR-TB drug resistant TB, ART antiretroviral therapy, RIF rifampicin p < 0.05 bold